EML4

Across TCGA pan-cancer cohorts, EML4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EML4 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EML4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EML4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where EML4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.582	0.907	.005	34	view →
CCRCC	DFS	Median	II,III,IV	0.979	0.163	.003	22	view →
PDAC	OS	Median	II,III,IV	0.926	0.736	.005	21	view →
LUAD	OS	Median	III,IV	0.665	0.235	.023	5	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.604	.042	4	view →
GBM	DFS	Tertile	All	0.504	0.246	.032	2	view →
LSCC	DFS	Median	All	0.622	0.799	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EML4–HNSC (OS)

Open the HNSC breakdown →